STOCK TITAN

Viridian Therapeutics to Participate in Cowen’s 43rd Annual Health Care Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

Viridian Therapeutics, Inc. (NASDAQ: VRDN) announced that its senior management will present at Cowen’s 43rd Annual Health Care Conference on March 8, 2023, at 1:30 p.m. ET in Boston, MA. A live webcast of the presentation will be available in the Investors section of Viridian's website. The company specializes in developing innovative medicines for serious and rare diseases, focusing on thyroid eye disease (TED). Currently, Viridian is advancing VRDN-001 through a global Phase 3 trial named ‘THRIVE’ and a Phase 2 proof-of-concept trial. The company aims to offer convenient treatment options for TED patients.

Positive
  • None.
Negative
  • None.

WALTHAM, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that senior management will present at Cowen’s 43rd Annual Health Care Conference on Wednesday, March 8, 2023 at 1:30 p.m. ET in Boston, MA.

A live webcast of the presentation can be accessed under “Events and Presentations” on the Investors section of the Viridian website at viridiantherapeutics.com. A replay of the webcast will be available following the completion of the event.

About Viridian Therapeutics

Viridian Therapeutics is a biopharmaceutical company focused on engineering and developing potential best-in-class medicines for patients with serious and rare diseases. Viridian’s expertise in antibody discovery and engineering enables it to develop differentiated therapeutic candidates for previously validated drug targets in commercially established disease areas.

Viridian is advancing multiple candidates in the clinic for the treatment of patients with thyroid eye disease (TED). The Company recently initiated its first global Phase 3 trial called ‘THRIVE’ to evaluate the safety and efficacy of VRDN-001 in patients with active TED. Viridian is also evaluating VRDN-001 in a Phase 2 proof-of-concept trial in patients with chronic TED. In addition to its intravenously administered VRDN-001 program, the Company is advancing two candidates for its subcutaneous strategy with the goal of providing a more conveniently administered therapy to patients with TED. Viridian is developing multiple preclinical assets in autoimmune and rare diseases.

Viridian is based in Waltham, Massachusetts. For more information, please visit www.viridiantherapeutics.com. Follow Viridian on LinkedIn.

Investor and Media Contacts:

Viridian Therapeutics, Inc.

Louisa Stone, 617-272-4604
Manager, Investor Relations
IR@viridiantherapeutics.com

Todd James, 617-272-4691
Senior Vice President, Corporate Affairs and Investor Relations
IR@viridiantherapeutics.com

Matt Fearer, 617-272-4605
Vice President, Corporate Communications
Media@viridiantherapeutics.com

Source: Viridian Therapeutics, Inc.

 


FAQ

What is the date and time of Viridian Therapeutics' presentation at Cowen's Annual Health Care Conference?

Viridian Therapeutics will present on March 8, 2023, at 1:30 p.m. ET.

Where can I watch the presentation by Viridian Therapeutics?

The presentation can be accessed via a live webcast in the Investors section of Viridian's website.

What clinical trials is Viridian Therapeutics currently conducting?

Viridian is conducting a global Phase 3 trial named ‘THRIVE’ and a Phase 2 proof-of-concept trial for VRDN-001.

What disease is Viridian Therapeutics focusing on with VRDN-001?

Viridian is focusing on thyroid eye disease (TED) with the VRDN-001 program.

What advancements is Viridian Therapeutics making for patients with TED?

Viridian is advancing multiple treatment candidates, including options for convenient subcutaneous administration.

Viridian Therapeutics, Inc.

NASDAQ:VRDN

VRDN Rankings

VRDN Latest News

VRDN Stock Data

1.59B
76.37M
0.01%
112%
13.12%
Biotechnology
Services-medical Laboratories
Link
United States of America
WALTHAM